Is first-line immune checkpoint inhibitors (ICI) beneficial to platinum-eligible patients (pts) with advanced urothelial carcinoma (aUC)? a meta-analysis.

被引：0
|
作者：
Cheng, Ce [1 ]
Chineke, Iloabueke Gabriel [1 ]
McBride, Ali [1 ]
Chipollini, Juan [1 ]
Gelmann, Edward Paul [1 ]
Recio-Boiles, Alejandro [1 ]
机构：
[1] Univ Arizona, Canc Ctr, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16506
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).
    Talukder, Rafee
    Bakaloudi, Dimitra Rafailia
    Lin, Genevieve Ihsiu
    Enright, Tom
    Leary, Jacob Beck
    Makrakis, Dimitrios
    Tripathi, Nishita
    Agarwal, Neeraj
    Jindal, Tanya
    Koshkin, Vadim S.
    Brown, Jason R.
    Johnson, Jeffrey
    Zakharia, Yousef
    Park, Joseph J.
    Alva, Ajjai Shivaram
    Barrera, Rafael Morales
    Drakaki, Alexandra
    Barata, Pedro C.
    Khaki, Ali Raza
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis
    Parikh, Ravi B.
    Feld, Emily K.
    Galsky, Matthew D.
    Adamson, Blythe J. S.
    Cohen, Aaron B.
    Baxi, Shrujal S.
    Ben Boursi, Shimon
    Christodouleas, John P.
    Vaughn, David J.
    Meropol, Neal J.
    Mamtani, Ronac
    FUTURE ONCOLOGY, 2020, 16 (02) : 4341 - 4345
  • [3] Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).
    Makrakis, Dimitrios
    Talukder, Rafee
    Dawsey, Scott
    Carril, Lucia
    Stewart, Tyler F.
    Morales-Barrera, Rafael
    Park, Joseph J.
    Fulgenzi, Claudia Angela Maria
    Murgic, Jure
    Vather-Wu, Naomi
    de Kouchkovsky, Ivan
    Devitt, Michael Edward
    Di Lorenzo, Giuseppe
    Gupta, Kavita
    Tripathi, Nishita
    Zakopoulou, Roubini
    Tripathi, Abhishek
    Lu, Eric
    Grivas, Petros
    Khaki, Ali Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [4] First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC).
    Agarwal, Archana
    Pond, Gregory Russell
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Barata, Pedro C.
    Garcia, Jorge A.
    Drakaki, Alexandra
    Lee, Jae-Lyun
    Kanesvaran, Ravindran
    Bilen, Mehmet Asim
    Lorenzo, Felipe R.
    Grivas, Petros
    Hussain, Syed A.
    Curran, Catherine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
    Khaki, Ali Raza
    Li, Ang
    Diamantopoulos, Leonidas N.
    Miller, Natalie J.
    Carril-Ajuria, Lucia
    Castellano, Daniel
    De Kouchkovsky, Ivan
    Koshkin, Vadim
    Park, Joseph
    Alva, Ajjai
    Bilen, Mehmet A.
    Stewart, Tyler
    Santos, Victor
    Agarwal, Neeraj
    Jain, Jayanshu
    Zakharia, Yousef
    Morales-Barrera, Rafael
    Devitt, Michael
    Nelson, Ariel
    Hoimes, Christopher J.
    Shreck, Evan
    Gartrell, Benjamin A.
    Sankin, Alex
    Tripathi, Abhishek
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Rodriguez-Vida, Alejo
    Drakaki, Alexandra
    Liu, Sandy
    Kumar, Vivek
    Lythgoe, Mark P.
    Pinato, David J.
    Murgic, Jure
    Frobe, Ana
    Joshi, Monika
    Velho, Pedro Isaacsson
    Hahn, Noah
    Buznego, Lucia Alonso
    Duran, Ignacio
    Moses, Marcus
    Barata, Pedro
    Galsky, Matthew D.
    Sonpavde, Guru
    Yu, Evan Y.
    Shankaran, Veena
    Lyman, Gary H.
    Grivas, Petros
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (03): : 464 - 472
  • [6] Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).
    Koshkin, Vadim S.
    Henderson, Nicholas
    Kilari, Deepak
    Jindal, Tanya
    Alhalabi, Omar
    Freeman, Dory
    Basu, Arnab
    Barata, Pedro C.
    Bilen, Mehmet Asim
    Zakharia, Yousef
    Emamekhoo, Hamid
    Shah, Sumit
    Milowsky, Matthew I.
    Davis, Nancy B.
    Gupta, Shilpa
    Hoimes, Christopher J.
    Grivas, Petros
    Bellmunt, Joaquim
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis
    Monteiro, Fernando Sabino Marques
    Soares, Andrey
    Mollica, Veronica
    Leite, Caio Abner
    Carneiro, Andre Paterno Castello Dias
    Rizzo, Alessandro
    Bourlon, Maria T.
    Sasse, Andre Deeke
    Santoni, Matteo
    Gupta, Shilpa
    Massari, Francesco
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 196
  • [8] Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts)
    Tzeng, Alice
    Diaz-Montero, C. Marcela
    Rayman, Patricia A.
    Kim, Jin Sub
    Pavicic, Paul G.
    Finke, James
    Barata, Pedro C.
    Lamenza, Marcelo
    Devonshire, Sarah
    Schach, Kim
    Emamekhoo, Hamid
    Ernstoff, Marc S.
    Hoimes, Christopher J.
    Rini, Brian I.
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ornstein, Moshe Chaim
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] Real-world prognostic model for overall survival (OS) in patients (pts) with advanced urothelial cancer (aUC) treated with immune checkpoint inhibitors (ICI)
    Khaki, Ali Raza
    Diamantopoulos, Leonidas Nikolaos
    Miller, Natalie J.
    Bilen, Mehmet Asim
    Santos, Victor Sacristan
    Morales-Barrera, Rafael
    Devitt, Michael Edward
    Nelson, Ariel Ann
    Shreck, Evan
    Assi, Hussein
    Zakopoulou, Roubini
    Rodriguez-Vida, Alejo
    Lythgoe, Mark
    Drakaki, Alexandra
    Joshi, Monika
    Velho, Pedro Isaacsson
    Alonso, Lucia
    Galsky, Matt D.
    Sonpavde, Guru
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [10] Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
    Cowzer, D.
    Capanu, M.
    Keane, F.
    Khalil, D.
    Shia, J.
    Do, R.
    Chou, J.
    Walch, H.
    El Dika, I.
    Yaqubie, A.
    Solit, D.
    Berger, M.
    O'Reilly, E.
    Harding, J.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S109 - S109
12345